[go: up one dir, main page]

EP2983785A1 - Supply of xenon or argon gas to a donor prior to taking a sample of biological material - Google Patents

Supply of xenon or argon gas to a donor prior to taking a sample of biological material

Info

Publication number
EP2983785A1
EP2983785A1 EP14720193.3A EP14720193A EP2983785A1 EP 2983785 A1 EP2983785 A1 EP 2983785A1 EP 14720193 A EP14720193 A EP 14720193A EP 2983785 A1 EP2983785 A1 EP 2983785A1
Authority
EP
European Patent Office
Prior art keywords
biological material
donor individual
gaseous
composition according
xenon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14720193.3A
Other languages
German (de)
French (fr)
Inventor
Ira Katz
Marc Lemaire
Jan Pype
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Original Assignee
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude filed Critical LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Publication of EP2983785A1 publication Critical patent/EP2983785A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to a gas or gaseous mixture of xenon or argon for administration to a donor of biological material, such as an organ or tissues, in particular a human being, prior to the removal of said organ or tissues so as to protect said biological material prior to its extraction from the body.
  • a donor of biological material such as an organ or tissues, in particular a human being
  • EP-A-2536272 teaches a liquid formulation comprising a liquid solution and at least one gas chosen from xenon, argon, hydrogen, H 2 S, helium, krypton, neon, radon or CO.
  • the gas is dissolved in the so-called liquid storage solution so as to preserve a biological material, in particular biological cells, tissues and organs, in particular an organ selected from the heart, the kidney, the liver, the pancreas and the body. 'intestine.
  • the gas is argon.
  • the problem is therefore to be able to avoid, reduce or minimize said ischemia-reperfusion injury by protecting as soon as possible biological material, including an organ.
  • the solution of the invention is a gaseous composition containing an active gaseous compound selected from the group consisting of Xe and Ar for use in preventing or minimizing ischemia-reperfusion injury of biological material in a donor individual, during and or after the removal of said biological material from said donor individual, said gaseous composition being administered to the donor individual prior to the removal of the biological material from said donor individual.
  • the gaseous composition of the invention may comprise one or more of the following technical characteristics:
  • the active gaseous compound is argon.
  • the active gaseous compound is xenon.
  • the biological material is a tissue, an organ or cells.
  • the biological material is an organ.
  • the biological material is an organ chosen from the liver, the kidneys, the lungs and the heart.
  • the active gaseous compound is mixed with an oxygen-containing gas, prior to its administration to the donor individual.
  • the donor individual is a human being, that is to say a man, a woman, a child, a newborn ...
  • a gaseous composition containing an active gaseous compound selected from argon and xenon mixed with oxygen can be used in a therapeutic treatment method for preventing or minimizing ischemia injury.
  • a donor individual such as a human being
  • the gaseous composition is administered to the donor individual, preferably by inhalation, prior to the removal of the biological material from said donor individual.
  • the duration of administration of the gas is easily determined by simple routine tests, depending on the organ to be extracted and the individual considered.
  • the invention also relates to a method for taking biological material from a donor individual whose heart is stopped, characterized in that said donor individual whose heart is stopped, a gaseous composition containing an active gaseous compound selected from the group formed by xenon (Xe) and argon (Ar), prior to and / or during removal of said biological material from said donor individual so as to prevent or minimize ischemia-reperfusion injury of said biological material.
  • a gaseous composition containing an active gaseous compound selected from the group formed by xenon (Xe) and argon (Ar), prior to and / or during removal of said biological material from said donor individual so as to prevent or minimize ischemia-reperfusion injury of said biological material.
  • the method of the invention may comprise one or more of the following technical characteristics:
  • the donor individual is a human being.
  • the biological material is an organ chosen from the liver, the kidneys, the lungs and the heart.
  • the gaseous composition contains at least 20% by volume of said active gaseous compound.
  • the gaseous composition contains between 15 and 80% by volume of said active gaseous compound.
  • said biological material is brought into contact with argon or xenon, preferably in gaseous form or in liquid form, that is to say by perfusion.
  • a gaseous composition according to the invention formed of a gaseous mixture of xenon or argon, and oxygen to prevent or minimize ischemia-reperfusion injury of a biological material in a individual donors, namely ischemia-reperfusion lesions of the lungs of pigs and mice
  • the gaseous mixtures Ar / 0 2 and Xe / 0 2
  • the gaseous composition is administered to the animals by inhalation, the animals being intubated and supplied with gas by a respiratory fan.
  • compositions tested contain levels of Ar or Xe of between 15 and 80% by volume, the balance being oxygen.
  • the administration of the gas began about 30 minutes before the removal of their lungs. However, this period can vary from a few minutes to several hours.
  • a virtual harvest of the animal's lungs is performed by clamping the lungs, arteries and veins connected to the lungs so as to obtain a total exclusion of the lungs from the body of the animals in a manner identical to an actual extraction.
  • a group of control animals is treated in the same way but with gaseous mixtures of nitrogen and oxygen (N 2 / O 2 ) in the same proportions.
  • the animals are sacrificed and the lungs are extracted and subjected to anatomical studies to determine the ischemic state, ie the presence of any lesions due to the period of ischemia-reperfusion.
  • compositions according to the invention based on argon or xenon, reduce the ischemia-reperfusion lesions, and their consequences on the good functioning of the lungs, unlike the animals in the control group having inhaled mixtures based on nitrogen.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

The invention relates to a gaseous composition containing an active gaseous compound selected from the group made up of Xe and Ar to be used for preventing or minimising an ischaemia-reperfusion lesion of a biological material in a donor patient, while and/or immediately after taking a sample of said biological material from said donor patient, said gaseous composition being administered to the donor patient prior to taking the sample of biological material from said donor patient.

Description

DELIVRANCE XÉNON OU ARGON GAZEUX A UN DONNEUR AVANT UN PRELEVEMENT DE  XENON OR GAS ARGON DELIVERANCE HAS A DONOR BEFORE TAKING
MATERIEL BIOLOGIQUE  BIOLOGICAL EQUIPMENT
La présente invention concerne un gaz ou mélange gazeux de xénon ou d'argon destiné à être administré à un donneur de matériel biologique, tel un organe ou des tissus, en particulier un être humain, préalablement au prélèvement dudit organe ou desdits tissus de manière à protéger ledit matériel biologique avant son extraction du corps. The present invention relates to a gas or gaseous mixture of xenon or argon for administration to a donor of biological material, such as an organ or tissues, in particular a human being, prior to the removal of said organ or tissues so as to protect said biological material prior to its extraction from the body.
Le prélèvement de matériel biologique, c'est-à-dire d'un ou plusieurs organes et/ou tissus, chez un individu, appelé donneur, est un acte chirurgical à finalité thérapeutique conduisant à une greffe, c'est-à-dire à la réimplantation du matériel biologique, appelé greffon, chez un autre individu, appelé receveur.  The collection of biological material, that is to say one or more organs and / or tissues, in an individual, called a donor, is a surgical procedure for therapeutic purpose leading to a transplant, that is to say the reimplantation of the biological material, called graft, into another individual called the recipient.
Afin d'éviter ou minimiser les détériorations de ce matériel biologique, c'est-à-dire de ces organes et/ou tissus, il est nécessaire de les protéger avec des solutions spécifiques, dites de préservation, voire avec des gaz spécifiques, avec lesquels les organes et/ou tissus sont mis en contact après leur prélèvement.  In order to avoid or minimize the deterioration of this biological material, that is to say of these organs and / or tissues, it is necessary to protect them with specific solutions, called preservation solutions, or even with specific gases, with which organs and / or tissues are brought into contact after being removed.
Ainsi, le document EP-A-2536272 enseigne une formulation liquide comprenant une solution liquide et au moins un gaz choisi parmi le xénon, l'argon, l'hydrogène, le H2S, l'hélium, le krypton, le néon, le radon ou le CO. Le gaz est dissous dans la solution liquide dite de conservation de sorte de conserver une matière biologique, en particulier des cellules, des tissus et des organes biologiques, en particulier un organe choisi parmi le cœur, le rein, le foie, le pancréas et l'intestin. De préférence, le gaz est de l'argon. Thus, EP-A-2536272 teaches a liquid formulation comprising a liquid solution and at least one gas chosen from xenon, argon, hydrogen, H 2 S, helium, krypton, neon, radon or CO. The gas is dissolved in the so-called liquid storage solution so as to preserve a biological material, in particular biological cells, tissues and organs, in particular an organ selected from the heart, the kidney, the liver, the pancreas and the body. 'intestine. Preferably, the gas is argon.
Or, entre le moment du prélèvement et la mise en contact du matériel biologique avec le milieu de conservation, il peut se produire des détériorations dudit matériel biologique, notamment des lésions d'ischémie-reperfusion qui sont délétères pour le matériel biologique.  However, between the time of sampling and the contact of the biological material with the preservation medium, there may be damage to said biological material, including ischemia-reperfusion injury which is deleterious to the biological material.
Le problème est dès lors de pouvoir éviter, réduire ou minimiser lesdites lésions d'ischémie-reperfusion en opérant une protection aussi tôt que possible du matériel biologique, notamment d'un organe.  The problem is therefore to be able to avoid, reduce or minimize said ischemia-reperfusion injury by protecting as soon as possible biological material, including an organ.
La solution de l'invention est une composition gazeuse contenant un composé gazeux actif choisi dans le groupe formé par Xe et Ar pour une utilisation pour prévenir ou minimiser une lésion d'ischémie-reperfusion d'un matériel biologique chez un individu donneur, lors et/ou consécutivement au prélèvement dudit matériel biologique chez ledit individu donneur, ladite composition gazeuse étant administrée à l'individu donneur préalablement au prélèvement du matériel biologique chez ledit individu donneur. Selon le cas, la composition gazeuse de l'invention peut comprendre l'une ou plusieurs des caractéristiques techniques suivantes : The solution of the invention is a gaseous composition containing an active gaseous compound selected from the group consisting of Xe and Ar for use in preventing or minimizing ischemia-reperfusion injury of biological material in a donor individual, during and or after the removal of said biological material from said donor individual, said gaseous composition being administered to the donor individual prior to the removal of the biological material from said donor individual. Depending on the case, the gaseous composition of the invention may comprise one or more of the following technical characteristics:
- le composé gazeux actif est de l'argon.  the active gaseous compound is argon.
- le composé gazeux actif est du xénon.  the active gaseous compound is xenon.
- elle contient un ou plusieurs composés gazeux additionnels choisis parmi N2, H2, He,it contains one or more additional gaseous compounds chosen from N 2 , H 2 , He,
H2S, Kr, Ne, NO et CO. H 2 S, Kr, Ne, NO and CO.
- elle contient entre 15 et 80% en volume du composé gazeux actif.  it contains between 15 and 80% by volume of the active gaseous compound.
- elle contient au moins 20% en volume dudit composé gazeux actif.  it contains at least 20% by volume of said active gaseous compound.
- elle contient au plus 60%> en volume dudit composé gazeux actif.  it contains at most 60% by volume of said active gaseous compound.
- le matériel biologique est un tissu, un organe ou des cellules.  - the biological material is a tissue, an organ or cells.
- le matériel biologique est un organe.  - the biological material is an organ.
- le matériel biologique est un organe choisi parmi le foie, les reins, les poumons et le cœur.  - the biological material is an organ chosen from the liver, the kidneys, the lungs and the heart.
- le composé gazeux actif est mélangé avec un gaz contenant de l'oxygène, préalablement à son administration à l'individu donneur.  the active gaseous compound is mixed with an oxygen-containing gas, prior to its administration to the donor individual.
- elle contient éventuellement de l'oxygène.  it possibly contains oxygen.
- l'individu donneur est un être humain, c'est-à-dire un homme, une femme, un enfant, un nouveau né...  - the donor individual is a human being, that is to say a man, a woman, a child, a newborn ...
- elle est administrée à un individu donneur sain.  - it is administered to a healthy donor individual.
- elle est administrée à un individu donneur dont le cœur bât.  - it is administered to a donor individual whose heart is bad.
- elle est administrée à un individu donneur dont le cœur est arrêté.  - it is administered to a donor individual whose heart is stopped.
- elle est administrée sous forme gazeuse par inhalation.  - It is administered in gaseous form by inhalation.
- elle est sous forme gazeuse et est administrée par inhalation au moyen d'un masque respiratoire ou une sonde d'intubation.  it is in gaseous form and is administered by inhalation by means of a respiratory mask or an intubation probe.
Plus généralement, dans le cadre de la présente invention, il a été mis en évidence que pour réduire les détériorations ou lésions résultant d'ischémies-reperfusions au sein d'organes ou autres tissus biologiques prélevés chez un individu donneur et destinés à être réimplantés et greffés chez un individu receveur, il convient d'agir préalablement à l'extraction chirurgicale desdits organes ou tissus biologiques en administrant une composition gazeuse protectrice à base de xénon ou d'argon au donneur.  More generally, in the context of the present invention, it has been demonstrated that to reduce deteriorations or lesions resulting from ischemia-reperfusions in organs or other biological tissues taken from a donor individual and intended to be reimplanted and grafted in a recipient individual, it is appropriate to act prior to the surgical extraction of said biological organs or tissues by administering a protective gaseous composition based on xenon or argon to the donor.
En d'autres termes, une composition gazeuse contenant un composé gazeux actif choisi dans l'argon et le xénon en mélange avec de l'oxygène, peut être utilisée dans une méthode de traitement thérapeutique visant à prévenir ou à minimiser une lésion d'ischémie-reperfusion d'un matériel biologique chez un individu donneur, tel un être humain, lors et/ou consécutivement au prélèvement dudit matériel biologique chez ledit individu donneur, dans laquelle la composition gazeuse est administrée à l'individu donneur, préférentiellement par inhalation, préalablement au prélèvement du matériel biologique chez ledit individu donneur. In other words, a gaseous composition containing an active gaseous compound selected from argon and xenon mixed with oxygen can be used in a therapeutic treatment method for preventing or minimizing ischemia injury. -reperfusion of biological material in a donor individual, such as a human being, during and / or consecutively sampling of said biological material from said donor individual, wherein the gaseous composition is administered to the donor individual, preferably by inhalation, prior to the removal of the biological material from said donor individual.
La durée d'administration du gaz, est aisément déterminable, via de simples essais de routine, en fonction de l'organe à extraire et de l'individu considéré.  The duration of administration of the gas is easily determined by simple routine tests, depending on the organ to be extracted and the individual considered.
L'invention concerne aussi un procédé pour prélever un matériel biologique chez un individu donneur dont le cœur est arrêté, caractérisé en ce qu'on administre audit individu donneur dont le cœur est arrêté, une composition gazeuse contenant un composé gazeux actif choisi dans le groupe formé par le xénon (Xe) et l'argon (Ar), préalablement et/ou lors du prélèvement dudit matériel biologique chez ledit individu donneur de manière à prévenir ou à minimiser une lésion d'ischémie-reperfusion dudit matériel biologique.  The invention also relates to a method for taking biological material from a donor individual whose heart is stopped, characterized in that said donor individual whose heart is stopped, a gaseous composition containing an active gaseous compound selected from the group formed by xenon (Xe) and argon (Ar), prior to and / or during removal of said biological material from said donor individual so as to prevent or minimize ischemia-reperfusion injury of said biological material.
Selon le cas, le procédé de l'invention peut comprendre l'une ou plusieurs des caractéristiques techniques suivantes :  Depending on the case, the method of the invention may comprise one or more of the following technical characteristics:
- l'individu donneur est un être humain.  - the donor individual is a human being.
- le matériel biologique est un organe choisi parmi le foie, les reins, les poumons et le cœur.  - the biological material is an organ chosen from the liver, the kidneys, the lungs and the heart.
- la composition gazeuse contient au moins 20% en volume dudit composé gazeux actif. the gaseous composition contains at least 20% by volume of said active gaseous compound.
- la composition gazeuse contient entre 15 et 80% en volume dudit composé gazeux actif.the gaseous composition contains between 15 and 80% by volume of said active gaseous compound.
- consécutivement au prélèvement du matériel biologique, ledit matériel biologique est mis en contact avec de l'argon ou du xénon, de préférence sous forme gazeuse ou sous forme liquide, c'est-à-dire par perfusion. - Following the collection of biological material, said biological material is brought into contact with argon or xenon, preferably in gaseous form or in liquid form, that is to say by perfusion.
Exemple illustratif Illustrative example
Afin de montrer l'efficacité d'une composition gazeuse selon l'invention formé d'un mélange gazeux de xénon ou d'argon, et d'oxygène pour prévenir ou minimiser les lésions d'ischémie-reperfusion d'un matériel biologique chez un individu donneur, à savoir ici les lésions d'ischémie-reperfusion des poumons de porcs et de souris, on a administré par inhalation les mélanges gazeux (Ar/02 et Xe/02) aux animaux anesthésiés (par propofol), préalablement au prélèvement de leurs poumons. In order to show the effectiveness of a gaseous composition according to the invention formed of a gaseous mixture of xenon or argon, and oxygen to prevent or minimize ischemia-reperfusion injury of a biological material in a individual donors, namely ischemia-reperfusion lesions of the lungs of pigs and mice, the gaseous mixtures (Ar / 0 2 and Xe / 0 2 ) were administered by inhalation to anesthetized animals (by propofol), prior to taking off their lungs.
La composition gazeuse est administrée aux animaux par inhalation, les animaux étant intubés et alimentés en gaz par un ventilateur respiratoire.  The gaseous composition is administered to the animals by inhalation, the animals being intubated and supplied with gas by a respiratory fan.
Les compositions testées contiennent des teneurs en Ar ou en Xe comprises entre 15 et 80%) en volume, le reste étant de l'oxygène. Ici, l'administration du gaz a débuté environ 30 minutes, avant le prélèvement de leurs poumons. Toutefois, cette période peut varier de quelques minutes à plusieurs heures. The compositions tested contain levels of Ar or Xe of between 15 and 80% by volume, the balance being oxygen. Here, the administration of the gas began about 30 minutes before the removal of their lungs. However, this period can vary from a few minutes to several hours.
Ensuite, on opère un prélèvement virtuel des poumons des animaux par clampage des poumons, des artères et veines reliées aux poumons de manière à obtenir une exclusion totale des poumons du corps des animaux de manière identique à une extraction réelle.  Then, a virtual harvest of the animal's lungs is performed by clamping the lungs, arteries and veins connected to the lungs so as to obtain a total exclusion of the lungs from the body of the animals in a manner identical to an actual extraction.
Une fois le clampage réalisé, on attend pendant une période d'environ 90 minutes, puis on opère un déclampage des poumons, veines et artères.  Once the clamping is done, one waits for a period of approximately 90 minutes, then one operates a declamping of the lungs, veins and arteries.
Un groupe d'animaux témoins est traité de la même manière mais avec des mélanges gazeux d'azote et d'oxygène (N2/02) dans les mêmes proportions. A group of control animals is treated in the same way but with gaseous mixtures of nitrogen and oxygen (N 2 / O 2 ) in the same proportions.
Ensuite, des tests de la fonction ventilatoire des poumons sont réalisés.  Then, tests of the ventilatory function of the lungs are carried out.
Puis, les animaux sont sacrifiés et es poumons sont extraits et soumis à des études anatomiques pour déterminer l'état ischémique, c'est-à-dire la présence de lésions éventuelles dues à la période d'ischémie-reperfusion.  Then, the animals are sacrificed and the lungs are extracted and subjected to anatomical studies to determine the ischemic state, ie the presence of any lesions due to the period of ischemia-reperfusion.
Les résultats obtenus montrent que les compositions selon l'invention, à base d'argon ou de xénon, diminuent les lésions d'ischémie-reperfusion, et leurs conséquences sur le bon fonctionnement des poumons, contrairement aux animaux du groupe témoin ayant inhalé des mélanges à base d'azote.  The results obtained show that the compositions according to the invention, based on argon or xenon, reduce the ischemia-reperfusion lesions, and their consequences on the good functioning of the lungs, unlike the animals in the control group having inhaled mixtures based on nitrogen.
Ces essais montrent l'intérêt à administrer une composition gazeuse selon l'invention à un individu donneur préalablement au prélèvement du matériel biologique chez ledit individu donneur.  These tests show the interest in administering a gaseous composition according to the invention to a donor individual prior to the removal of the biological material from said donor individual.

Claims

Revendications claims
1. Composition gazeuse contenant un composé gazeux actif choisi dans le groupe formé par le xénon (Xe) et l'argon (Ar) pour une utilisation pour prévenir ou minimiser une lésion d'ischémie-reperfusion d'un matériel biologique chez un individu donneur, lors et/ou consécutivement au prélèvement dudit matériel biologique chez ledit individu donneur, ladite composition gazeuse étant administrée à l'individu donneur préalablement au prélèvement du matériel biologique chez ledit individu donneur. A gaseous composition containing an active gaseous compound selected from the group consisting of xenon (Xe) and argon (Ar) for use in preventing or minimizing ischemia-reperfusion injury of biological material in a donor individual during and / or subsequent to the removal of said biological material from said donor individual, said gaseous composition being administered to the donor individual prior to the removal of the biological material from said donor individual.
2. Composition selon la revendication précédente, caractérisée en ce qu'elle contient entre 15 et 80% en volume dudit composé gazeux actif. 2. Composition according to the preceding claim, characterized in that it contains between 15 and 80% by volume of said active gaseous compound.
3. Composition selon l'une des revendications précédentes, caractérisée en ce que le matériel biologique est un tissu, un organe ou des cellules. 3. Composition according to one of the preceding claims, characterized in that the biological material is a tissue, an organ or cells.
4. Composition selon l'une des revendications précédentes, caractérisée en ce que le matériel biologique est un organe. 4. Composition according to one of the preceding claims, characterized in that the biological material is an organ.
5. Composition selon l'une des revendications précédentes, caractérisée en ce que le matériel biologique est un organe choisi parmi le foie, les reins, les poumons et le cœur. 5. Composition according to one of the preceding claims, characterized in that the biological material is an organ selected from the liver, kidneys, lungs and heart.
6. Composition selon l'une des revendications précédentes, caractérisée en ce que le composé gazeux actif est mélangé avec un gaz contenant de l'oxygène, préalablement à son administration à l'individu donneur. 6. Composition according to one of the preceding claims, characterized in that the active gaseous compound is mixed with an oxygen-containing gas, prior to its administration to the donor individual.
7. Composition selon l'une des revendications précédentes, caractérisée en ce que l'individu donneur est un être humain. 7. Composition according to one of the preceding claims, characterized in that the donor individual is a human being.
8. Composition selon l'une des revendications précédentes, caractérisée en ce qu'elle est administrée à un individu donneur sain. 8. Composition according to one of the preceding claims, characterized in that it is administered to a healthy donor individual.
9. Composition selon l'une des revendications précédentes, caractérisée en ce qu'elle est administrée à un individu donneur dont le cœur est arrêté. 9. Composition according to one of the preceding claims, characterized in that it is administered to a donor individual whose heart is stopped.
10. Composition selon l'une des revendications précédentes, caractérisée en ce qu'elle est administrée sous forme gazeuse par inhalation. 10. Composition according to one of the preceding claims, characterized in that it is administered in gaseous form by inhalation.
11. Procédé pour prélever un matériel biologique chez un individu donneur dont le cœur est arrêté, caractérisé en ce qu'on administre audit individu donneur dont le cœur est arrêté, une composition gazeuse contenant un composé gazeux actif choisi dans le groupe formé par le xénon (Xe) et l'argon (Ar), préalablement et/ou lors du prélèvement dudit matériel biologique chez ledit individu donneur de manière à prévenir ou à minimiser une lésion d'ischémie- reperfusion dudit matériel biologique. 11. A method for taking biological material from a donor individual whose heart is stopped, characterized in that said donor individual whose heart is stopped, a gaseous composition containing an active gaseous compound selected from the group formed by xenon (Xe) and argon (Ar), prior to and / or during removal of said biological material from said donor individual to prevent or minimize ischemia-reperfusion injury of said biological material.
12. Procédé selon la revendication 11, caractérisé en ce que l'individu donneur est un être humain. 12. The method of claim 11, characterized in that the donor individual is a human being.
13. Procédé selon l'une des revendications 1 1 ou 12, caractérisé en ce que le matériel biologique est un organe choisi parmi le foie, les reins, les poumons et le cœur. 13. Method according to one of claims 1 1 or 12, characterized in that the biological material is an organ selected from the liver, kidneys, lungs and heart.
14. Procédé selon l'une des revendications 11 à 13, caractérisé en ce que la composition gazeuse contient entre 15 et 80% en volume dudit composé gazeux actif. 14. Method according to one of claims 11 to 13, characterized in that the gaseous composition contains between 15 and 80% by volume of said active gaseous compound.
15. Procédé selon l'une des revendications 11 à 14, caractérisé en ce que, consécutivement au prélèvement du matériel biologique, ledit matériel biologique est mis en contact avec de l'argon ou du xénon, de préférence sous forme gazeuse ou sous forme liquide. 15. Method according to one of claims 11 to 14, characterized in that, following the removal of the biological material, said biological material is brought into contact with argon or xenon, preferably in gaseous form or in liquid form. .
EP14720193.3A 2013-04-12 2014-04-09 Supply of xenon or argon gas to a donor prior to taking a sample of biological material Withdrawn EP2983785A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1353312A FR3004312A1 (en) 2013-04-12 2013-04-12 DELIVERANCE OF MEDICAL GAS TO A DONOR BEFORE TESTING BIOLOGICAL EQUIPMENT
PCT/FR2014/050848 WO2014167245A1 (en) 2013-04-12 2014-04-09 Supply of xenon or argon gas to a donor prior to taking a sample of biological material

Publications (1)

Publication Number Publication Date
EP2983785A1 true EP2983785A1 (en) 2016-02-17

Family

ID=48906289

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14720193.3A Withdrawn EP2983785A1 (en) 2013-04-12 2014-04-09 Supply of xenon or argon gas to a donor prior to taking a sample of biological material

Country Status (6)

Country Link
US (1) US20160051580A1 (en)
EP (1) EP2983785A1 (en)
CN (1) CN105102064A (en)
CA (1) CA2908019A1 (en)
FR (1) FR3004312A1 (en)
WO (1) WO2014167245A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0415616A (en) * 2003-10-21 2006-12-12 Aga Ab use of xenon to prevent programmed cell death
EP1552840A1 (en) * 2004-01-07 2005-07-13 Aga Ab Use of a xenon/carbon monoxide mixture for the protection of cells
GB0520176D0 (en) * 2005-10-04 2005-11-09 Imp College Innovations Ltd Use
FR2956323B1 (en) * 2010-02-15 2013-12-20 Air Liquide ARGON-BASED INHALABLE GAS MEDICINE AGAINST PERIPHERAL ORGAN DEFECTS OR MALFUNCTIONS
FR2956289B1 (en) 2010-02-18 2014-09-19 Air Liquide LIQUID FORMULATION WITH DISSOLVED GASES FOR PRESERVING BIOLOGICAL MATERIAL

Also Published As

Publication number Publication date
CA2908019A1 (en) 2014-10-16
US20160051580A1 (en) 2016-02-25
FR3004312A1 (en) 2014-10-17
WO2014167245A1 (en) 2014-10-16
CN105102064A (en) 2015-11-25

Similar Documents

Publication Publication Date Title
WO2014167244A1 (en) Delivery of argon to a recipient of biological material
MXPA03012031A (en) Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis.
JP2013522311A (en) Combination therapy with cyclosporine and aromatic-cationic peptide
US20080139669A1 (en) Use of a blood-flow decrease preventing agent in conjunction with insufflating gas
JP2006514621A5 (en)
Chiari et al. Myocardial protection in cardiac surgery: a comprehensive review of current therapies and future cardioprotective strategies
EP2536415B1 (en) Gaseous inhalable medicament comprising argon gas against peripheral organ deficiencies or failures
AU2004283448B2 (en) Use of xenon for the prevention of programmed cell death
AU2002316337A1 (en) Use of a blood-flow decrease preventing agent in conjunction with insufflating gas
WO2005067945A2 (en) Use of a xenon/carbon monoxide mixture for the protection of cells
EP2983785A1 (en) Supply of xenon or argon gas to a donor prior to taking a sample of biological material
Ramlawi et al. Inhaled carbon monoxide prevents graft-induced intimal hyperplasia in swine
Lindberg et al. Inhaled nitric oxide reveals and attenuates endothelial dysfunction after lung transplantation
DE10336768B4 (en) Drug for improving oxygenutilation
Altunkaya et al. Role of the nitric oxide pathway in ischemia-reperfusion injury in isolated perfused guinea pig lungs
FR2960779A1 (en) INHALABLE GASEOUS MEDICINE BASED ON KRYPTON AGAINST PERIPHERAL ORGAN DEFECTS OR FAILURES
US20230233462A1 (en) Topical solution of efinaconazole with high subungual penetration
DE10336778A1 (en) Inhalable medicament for stabilizing patients, e.g. during operations, useful e.g. for treating hypotension, shock, ischemia or reperfusion damage, comprising xenon
Novick Preservation of the hypertrophied pig heart: a comparison of crystalloid, blood, and fluosol cardioplegia during prolonged aortic clamping
Lee et al. An Influence of a Combined Administration of Propofol and Isoflurane on Antioxidative Enzyme Activities in Growing Swine Erythrocytes
US20060233714A1 (en) Use of a volatile liquid at atmospheric pressure and ambient temperature for the production of pharmaceutical or biological compositions
Morgaz et al. World Journal of
MXPA06004505A (en) Use of xenon for the prevention of programmed cell death

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160803

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161214